Carbon-11-MK 6884

Drug Profile

Carbon-11-MK 6884

Alternative Names: [11C]MK-6884; C-11-MK-6884; MK-6884

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antidementias; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 28 Dec 2017 Merck Sharp & Dohme Corp. completes a phase I trial in Alzheimer's disease (Diagnosis, In the elderly, In adults) in Belgium (IV) (NCT02621606)
  • 01 Jan 2016 Phase-I clinical trials in Alzheimer's disease (Diagnosis, In the elderly, In adults) in Belgium (IV) (NCT02621606)
  • 16 Dec 2015 Merck Sharp & Dohme plans a phase I trial for Alzheimer's disease (Diagnosis) in USA (IV) (NCT02621606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top